Tuesday Aug 26
Sanofi SA Reaches New 52-Week High at $54.95
Sanofi SA reached a new 52-week high during mid-day trading on Tuesday , Analyst Ratings Net reports.
Tuesday Aug 26
Why I Bought Into Monday's Move In Regeneron
Valuation may explain why there is a decent short position on the stock, but the shorts may be getting uncomfortable now.
Mon Aug 25, 2014
The 4 Companies Teaming Up For A New Tool To Fight Cancer
Big pharma and one relatively small company are teaming up to develop a master test that will help doctors pick a combination of drugs tailored to the individual patient's condition.
Thu Aug 21, 2014
Investor's Business Daily
Illumina lines up key partners
Illumina shares fell0.5% to 172.09. AstraZeneca rose 3.1% to 73.19 and Sanofi rose 1.8% to 53.74.
Wed Aug 13, 2014
Option Bulls Active as InterMune Inc (ITMN) Soars On Buyout Buzz
InterMune Inc has tacked on 13.7% this afternoon to trade at $51.74, after earlier notching a decade-plus high of $54.57.
's M&A Chatter for Wednesday August 13, 2014
The Rumor : Shares of Intermune spiked sharply higher Wednesday, on a report from Bloomberg that Sanofi and Roche had submitted bids for the Brisbane, CA-based biotech company, according to sources.
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune
Disclosure: I am long on MannKind. Introduction On August 11, 2014, investors witnessed MannKind's partnership announcement stating the company has entered into collaboration and a licensing agreement with Sanofi SA .
Mon Aug 11, 2014
Why The Sanofi Deal Is The Best Possible Deal For MannKind Investors
The suspense is over. As reported by Bloomberg ,"French insulin maker Sanofi will "pay $150 million up front and as much as $775 million if the drug, Afrezza, meets certain sales and development targets."
Sanofi Appears To Be In The Early Stages Of An Earnings Rebound
Sanofi , the subject of this article, is one of the oldest and largest pharmaceutical concerns in the world, competing in the same league as world-class enterprises Novartis , Pfizer , Glaxo , and Merck .
Requiem for a son: Voucher program speeds drugs aimed at childhood diseases
Brain cancer killed Nancy Goodman 's 10-year-old son Jacob, but no one was happier than Goodman when Regeneron Pharmaceuticals Inc. and Sanofi SA asked the Food and Drug Administration for speedy approval of a cholesterol-fighting drug.
Fri Aug 08, 2014
Sanofi SA Given Consensus Rating of "Hold" by Analysts
Sanofi SA has earned an average rating of "Hold" from the ten ratings firms that are presently covering the stock, Analyst RN reports .
Thu Aug 07, 2014
Sanofi: Confronting Lantus Patent Expiry With More Efficient Successor Toujeo
Sanofi received the US FDA's acceptance for reviewing its New Drug Application for investigational basal insulin, Toujeo.
Sanofi Licenses Immune Design's GLAAS Platform to Explore Novel Approach to Treat Food Allergy
Sanofi and Immune Design , a clinical-stage immunotherapy company, today announced that they have entered into a licensing agreement for use of Immune Design's GLAASTM discovery platform to develop therapeutic agents to treat a selected food allergy.
Mon Aug 04, 2014
Sanofi SA Receives Average Recommendation of "Hold" from Brokerages
Shares of Sanofi SA have been given a consensus recommendation of "Hold" by the eleven ratings firms that are covering the stock, StockRatingsNetwork.com reports .
Thu Jul 31, 2014
Sanofi SA (SNY) Announces Quarterly Earnings, Misses Expectations By $0.07 EPS
Sanofi SA issued its quarterly earnings data on Thursday. The company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.79 by $0.07, ARN reports.